May 30, 2019
By Christina Sandefur
One year ago, what seemed impossible became reality when the president signed the Right to Try Act — a federal law that protects patients’ right to seek medicines that have received basic safety approval by the Food and Drug Administration (FDA), but have not yet been fully approved for sale.
The Right to Try movement was genuine grassroots reform, passed by a majority of states before arriving in Congress. It received strong bipartisan support all the way.
It’s pretty unusual for state and federal legislators of both parties to come together on anything nowadays, especially a major piece of healthcare reform legislation. But patients have been trying for decades to break the bureaucratic inertia that has slowed their access to innovative treatments that could improve or even save their lives. They knew their time had finally come.
Christina Sandefur is the Executive Vice President at the Goldwater Institute.